Oncolytics Biotech Inc ONCY

PDAC

[pelaboost]

The company advises on its website that they are planning an adaptive Phase3 program and intends to manage it directly within its Clinical Group and a contract research organization (CRO) with the goal of enrolling the first patient in mid-2024.

That is crystal clear. They are going it alone, and one has to assume with the info on the new presentation that Roche has agreed to continue supplying Tecentriq.

Maybe Anson will be supplying the funds. They never seem to have thought these matters out very carefully. At least they do not give their shareholders anything solid upon which to make decisions.

[pelaboost]

CRO -  Contract Research Organization The CRO for GOBLET is AIO  -  Asklepios Tumorzentrum Hamburg Yet we have not been advised as to the CRO for the Adaptive Phase 3 Trial. From my lay position it seems to me AIO is the obvious choice for the Adaptive Phase 3 Trial. Alas shareholders are completely in the dark as to the CRO for the Phase 3 trial. ONC certainly knows the CRO

[Lesalpes29]

One Word...wow.

[13X2413]

That's why $1.40's are sneaking up on us. The ship has sailed. The supposed mid 2024 info was put out there to try to keep people interested as long as possible. 

[venture009]

Intersting find. Is this a recent update, does anyone know? Their Jan. 9/24 release announcing the appointment of Patricia S. Andrews to the board, they say, "As we begin preparations to initiate pivotal studies with pelareorep in breast and pancreatic cancers and progress partnering discussions, we look forward to benefitting from her insights and strategic and operational experience."

[CMHarring218431]

Venture...could not AIO be considered as a partner. After all, they would be doing all the work thus excluding ONC from hiring a whole new team to run with this.